Caspase-2 inhibitors have excellent, though unrealized, potential for improving cognition in patients with Alzheimer’s (AD), frontotemporal dementia (FTD), and Huntington’s disease (HD), based on the restorative effects of lowering caspase-2 in mouse models of these diseases. Our broad, long-term objective is to prepare safe and effective caspase-2 inhibitors to treat dementia. We recently discovered that caspase-2 forms a toxic tau fragment (Δtau314) in cell and mouse models of FTD. Δtau314 infiltrates dendritic spines and dislocates glutamate receptors, impairing synaptic function. Lowering caspase-2 in cells prevents tau from infiltrating spines, and reducing caspase-2 in the brain restores memory in impaired mice. We will employ this animal model to provide confidence in mechanism for our inhibitors, in order to exploit using Δtau314, the only known molecular biomarker of caspase-2 activity that is correlated with changes in cognition. Caspase-2 inhibitors have been reported but none are both selective and brain-penetrant. The failure of these compounds to advance to the clinic suggests the need for a radical shift in drug discovery paradigms. What is required is a paradigm that is built upon holistic assays (those that account for the complex interactions between caspases and intracellular components), rather than the conventional drug discovery approach based on assays employing recombinant enzymes. We propose to establish a holistic platform for the discovery of selective, safe, and effective caspase-2 inhibitors. We plan to accomplish this by pursuing the following specific aims: (1) preparation and assay of compounds inspired by Δtau314, the canonical inhibitor VDVAD-CHO (D-CHO = aspart-1-al), and other reported brain penetrant or selective caspase-2 inhibitors, (2) development of holistic assays to study the caspase activity and selectivity of compounds in brain cell lysates, and (3) mouse PK/PD (oral, sc, ip) studies on the best of these compounds to characterize their brain-distribution and ability to restore cognitive function.
Yueming Li, Ph.D.
Associate Member/Professor, Memorial Sloan-Kettering Cancer Center

“Development of TFEB target-based small molecules for Alzheimer's disease therapy”

The overall objective of this proposal is to develop small molecules that promote TFEB-mediated clearance of misfolded Tau proteins for treatment of Alzheimer’s disease (AD). Aberrant Tau phosphorylation, leading to the formation of intracellular neurofibrillary tangles (NFT) found in AD patient brains, is a hallmark of AD. The Transcription Factor EB (TFEB) was discovered as a master regulator for lysosomal biogenesis and autophagy. Our studies have shown that mild overexpression of TFEB potently reduces tauopathy, behavioral deficit and neurodegeneration in a Tau transgenic mouse model by activating autophagy and lysosomal degradation pathways indicating that upregulation of TFEB could be a promising strategy for AD therapy. In this application, we propose to first conduct a large-scale small molecule library screening to identify hits that target the TFEB pathway and generate lead compounds. Secondly, we will determine the therapeutic potential of the lead compounds in AD preclinical models. The proposed research consisting of chemical library screening, validation and analog synthesis, and in vivo testing will enable us to develop drug candidates that are effective in clearing the Tau/NFT pathologies for AD treatment.
Susan Lindquist, Ph.D.
Member, Professor of Biology, Whitehead Institute for Biomedical Research

“Bioactive Cyclic Peptides as Potential Therapeutics for Alzheimer’s Disease”

Alzheimer’s disease (AD) is characterized by toxic conformations of Amyloid-beta (Abeta) peptides. A poorly understood mechanism of Abeta’s toxic effect in neurons together with the lack of high-throughput screening systems against Abeta cytotoxicity has made the discovery of AD therapeutics difficult and painstakingly slow.

Exploiting the extraordinarily conserved pathways of protein trafficking and homeostasis in eukaryotes, we established powerful Abeta42 cytotoxic models anchored at one end by high-throughput yeast screens and validated at the other by human stem cell-derived neurons. Genome-wide screening in yeast identified genes as modulators of critical cellular pathways disrupted by Abeta toxicity. Importantly, human homologs of several of these genes are validated risk factors for AD (i.e., PICALM), thus corroborating the pathobiological relevance. Collaborating with the Harvard Institute of Chemistry and Cell Biology and the National Center for the Advancement of Translational Sciences, we screened >500,000 compounds and identified hit compounds (~150) that reverse toxicity in yeast. These compounds have now been licensed to Yumanity Therapeutics (http://yumanity.com) to ensure that their potential therapeutic applications are adequately explored. (Previous research on two of these compounds in the Lindquist laboratory was supported by the Thome Foundation.)

We have established additional cytotoxic models in yeast and neurons by expressing familial Abeta variants. Intriguingly, the familial Arctic mutation (E22G) strongly increased cytotoxicity. Remarkably, a non-toxic mutant, I31E, abrogates cytotoxicity of toxic Abeta variants in coexpression systems, emphasizing the importance of peptide biologics as potential therapeutics.

Recently, the therapeutic potential of biologics in medicine has begun to materialize. The early promise of the phase 3 clinical trial for aducanumab (Biogen Idec) as an antibody biologic is a ray of hope for AD therapy. Using our powerful cytotoxic models, we propose to isolate, characterize and validate cyclic peptides as potential AD therapeutics. These peptide biologics provide a novel paradigm for drug development.

Kun Ping Lu, M.D., Ph.D.
Edward N. and Della L. Thome Memorial Foundation, Bank of America, N.A. Trustee,
Awards Program in Alzheimer's Disease Drug Discovery Research
2015 Award Recipient

Professor of Medicine, Beth Israel Deaconess Medical Center

“Development of Novel Targeted Therapy for Alzheimer's Disease”

Prevalence of Alzheimer’s disease (AD) may quadruple worldwide by 2050, but effective treatment is not available. Tauopathy made of hyperphosphorylated tau is one hallmark lesion in AD. Immunization against tauopathy epitopes shows promising efficacy in mouse models. Tauopathy correlates well with memory decline in AD and is also a defining feature of other tauopathies, notably chronic traumatic encephalopathy (CTE). Significantly, one of the best-known environmental risk factors for CTE and AD is traumatic brain injury (TBI). However, tauopathy is not obvious in acute and subacute TBI and how TBI leads to tauopathy is unknown.

We have identified a unique proline isomerase Pin1 to inhibit tauopathy by converting the phosphorylated Thr231-Pro motif in tau (p-tau) from cis to trans conformation. By generating cis and trans p-tau antibodies, we have identified the early pathogenic cis tau leading to tauopathy in AD. We have now created high affinity monoclonal antibody (mAb) that effectively removes this early, secreted and toxic cis tau in vitro and in mice. Importantly, cis p-tau is an early precursor of tauopathy and an early driver of neurodegeneration that can be blocked by cis mAb. Our data provide a direct link from TBI to CTE and AD, and suggest that cis mAb may be further developed for early diagnosis and treatment of AD, TBI and CTE.

Here we will first humanize our cis p-tau mouse mAb and then characterize humanized mAbs and evaluate their potency to eliminate cis p-tau and inhibit cistauosis in vitro as well as to treat tauopathy in AD mouse models. The current proposal is the first and essential step of our ultimate goal to develop unique therapeutic mAb against the disease-driving early pathogenic tau for treating AD, raising the unique opportunity of halting or preventing tauopathy and memory loss in AD patients at early stages.
Edward N. and Della L. Thome Memorial Foundation, Bank of America, N.A. Trustee, 
Awards Program in Alzheimer’s Disease Drug Discovery Research 
2015 Award Recipient

Pamela Maher, Ph.D. 
Senior Staff Scientist, The Salk Institute

“Novel Glycation Inhibitors for the Treatment of Alzheimer’s Disease”

Age is the single greatest risk factor for Alzheimer’s disease (AD). Among the 
pathophysiological changes that have been proposed to contribute to the decrease in 
brain function with age are increases in protein glycation. Protein glycation, the non-
enzymatic addition of sugars to proteins, results in the formation of advanced glycation 
end-products (AGEs). This protein modification is increased during normal aging and 
is greatly exacerbated in AD suggesting that inhibitors of AGE formation may have 
potential for the treatment of AD. Glutathione (GSH), the major endogenous 
antioxidant, plays a critical role in the removal of the potent AGE precursor, 
methylglyoxal (MG). Loss of GSH occurs during aging suggesting that GSH 
maintenance should be an integral part of any approach to preventing the accumulation 
of AGEs. Fisetin was initially identified as an orally active, novel neuroprotective and 
cognition-enhancing molecule. Fisetin can protect nerve cells from multiple toxic insults 
and can increase the intracellular levels of GSH in the presence of oxidative stress. 
Furthermore, fisetin can inhibit protein glycation both in vitro and in vivo. We recently 
synthesized a series of much more potent fisetin derivatives, many of which maintain 
the ability to increase GSH levels. These derivatives have the potential to be good CNS 
drugs and do not suffer from the intellectual property challenges of the natural product 
fisetin. Based on these observations, it is proposed to advance fisetin derivatives as 
inhibitors of AGE accumulation for the treatment of AD. Specifically, the anti-glycation 
activity of the fisetin derivatives will be assayed in the test tube and in cell culture 
models of glycation. The most effective of these derivatives will be subjected to limited 
pharmacokinetic and toxicology studies. Based on these results, the two best derivatives 
will be tested in SAMP8 mice, a novel animal model of aging and AD.
Benjamin Wolozin, M.D., Ph.D.
Professor, Boston University School of Medicine

“Targeting RNA Metabolism and the Stress Granule Pathway to Inhibit Tau Aggregation”

RNA binding proteins (RBPs) use physiological aggregation to form inclusions composed of protein/RNA complexes that control of processes such as RNA transport, RNA translation and RNA degradation. For instance, stress causes RBPs to exit the nucleus where they form stress granules, which function to sequester away from the pool of translated transcripts facilitating translation of protective proteins.

We have discovered that RBPs, such as TIA1, co-localize with tau pathology. Further work shows that RBPs, such as TIA1, are important regulators of tau pathology. Knockdown or knockout of TIA1 inhibits tau (WT or P301L) aggregation and toxicity in neurons in vitro and in vivo, while TIA1 over-expression stimulates tau aggregation and toxicity. In Alzheimer’s disease, this pathway becomes hyperactive. The intimate link between tau, RBPs and neurodegeneration points to novel approaches to pharmacotherapy of tauopathies. RNA granules, including stress granules, are regulated by signaling networks. These networks can be pharmacologically modulated to reverse formation of both tau and RNA granules.

In this proposal our goal is to identify compounds that can reverse tau aggregation and toxicity associated with tau/TIA1 expression. We have generated a line of neuronal cells (human SY5Y cells) that inducibly express both tau and TIA1. Expressing both proteins together induces aggregated tau, tau inclusions and degeneration. In Aim 1 we will screen our tau/TIA1 cell line against a library of compounds selected for likely CNS penetration based on Lapinski’s rules. Two phenotypes will be selected as outcomes: Tau granule formation and neurotoxicity. Hits will be validated with dose response curves and then in assays of primary neuronal cultures expressing P301L tau. Tertiary validation will use biochemistry. Lead compounds will be tested for future studies in vivo. In Aim 2 we will investigate the ADME and pharmacokinetic properties of the most promising hits.
Edward N. and Della L. Thome Memorial Foundation, Bank of America, N.A. Trustee, Awards Program in Alzheimer’s Disease Drug Discovery Research 2012 Award Recipient

P. Jeffrey Conn, Ph.D.
Lee E. Limbird Professor of Pharmacology; Director, Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center

"In vivo characterization of metabotropic glutamate receptor subtype 5 positive allosteric modulators in a mouse model of Alzheimer’s disease”

Alzheimer disease (AD) is the most common form of dementia and is characterized by the progressive decline in cognitive function, with the primary deficits being hippocampal-mediated learning and memory loss. Recent studies suggest the involvement of glutamate in the pathology of the disease, as levels are decreased in the hippocampus of AD patients. Glutamate modulates excitatory postsynaptic currents via metabotropic glutamate receptors (mGlus). mGlu5 is the most highly expressed mGlu in the hippocampus and a close signaling partner of the N-Methyl-D-aspartate receptor (NMDAR). The NMDAR is critical in regulating hippocampal synaptic plasticity and essential for hippocampal-dependent cognitive function. Therefore, increased activation of mGlu5 offers an exciting new therapeutic strategy to enhance cognitive function in patients suffering from AD. Recently, our group has developed a highly potent, selective series of mGlu5 positive allosteric modulators (PAMs) with enhanced pharmacokinetic properties for in vivo studies, providing an unprecedented opportunity to evaluate the potential of selective potentiation of mGlu5 as a novel target for the treatment of symptoms associated with AD. Unlike orthosteric agonists, PAMs dramatically potentiate the receptor response to its endogenous ligand glutamate offering high selectivity while avoiding unwanted side-effects seen with direct activation. CK-p25 mice have a loss of hippocampal synaptic function as well as cognitive function, In addition, these mice exhibit the hallmark pathological and neurodegenerative features of AD and allow the opportunity to characterize the ability of our novel mGlu5 PAMs to restore cognitive deficits in a preclinical animal model that best emulates the human disease state. Studies proposed will establish the ability of mGlu5 PAMs to restore deficits in synaptic function, determine the degree of in vivo occupancy of central mGlu5 necessary to observe in vivo efficacy and evaluate the cognitive-enhancing efficacy of mGlu5 PAMs in preclinical models of cognitive function in an animal model of AD.
Philip De Jager, M.D., Ph.D.  
Associate Professor  
Harvard Medical School

"Identification of small molecules that modify CD33 expression"

With the discovery and validation of Alzheimer’s disease (AD) susceptibility loci, we now have AD risk factors that give insights into the earliest pathophysiological processes of AD. Specifically, recent genome-wide studies have identified nine non-APOE AD susceptibility loci: ABCA7, BIN1, CD2AP, CD33, CLU, CR1, EPHA1, MS4A, and PICALM. Several of these loci implicate the innate immune system in susceptibility to AD. Here, we focus on the CD33 locus and propose to identify compounds that block the functional consequences of the CD33 allele that increases an individual’s risk for AD. The proposal leverages the detailed functional characterization of this risk allele that we have conducted and highlights a disturbance in monocyte function that could play a broader role in AD susceptibility, beyond its mediation of the effect of a risk allele. CD33, an inhibitory molecule, expressed on the surface of myeloid progenitors, monocytes and macrophages that constitutively reduces the activity of myeloid cells. Our investigations have uncovered a robust molecular phenotype associated with the CD33 risk allele: it increases the surface expression of CD33 6-fold on circulating monocytes. This large effect on the state of activation of monocytes is present both in younger and older subjects, suggesting that the functional consequences of the CD33 locus may be exerted from the earliest stages of AD pathophysiology, which probably occur in middle age. We hypothesize that altered myeloid function driven by high CD33 expression contributes to the onset of AD, and therefore propose to identify chemical agents, using high throughput screening, that reduce CD33 surface concentration on monocytes of subjects with the risk allele to the levels seen on monocytes from subjects of the protective allele.
Edward N. and Della L. Thome Memorial Foundation, Bank of America, N.A. Trustee, Awards Program in Alzheimer’s Disease Drug Discovery Research 2012 Award Recipient

David Harris, M.D., Ph.D.
Professor and Chair
Boston University School of Medicine

"Prion Protein-Targeted Therapeutics for Alzheimer’s Disease”

The purpose of this application is to develop an entirely new class of therapeutic agents for Alzheimer’s disease, based on the recent identification of a novel drug target, the cellular prion protein (PrPC), which functions as a receptor for Abeta oligomers and may mediate their pathogenic effects. Small molecule ligands that bind to PrPC and block its interaction with Abeta oligomers may therefore represent powerful drugs to prevent neuronal and synaptic dysfunction in Alzheimer’s disease.

We have already identified several lead compounds that bind specifically and with high affinity to PrPC, and inhibit its interaction with Abeta oligomers, thus demonstrating unequivocally that PrPC is a druggable target. To accomplish this, we used in silico methods to predict probable ligand binding sites on the surface of PrPC, followed by a virtual screen of 17 million compounds to identify those that docked optimally in one of these sites. Candidate ligands were then validated experimentally using biophysical techniques to measure their affinity for PrPC, and methods developed by my laboratory to measure their effects on the functional activity of PrPC. Our most promising set of lead compounds bind tightly and specifically to PrPC and powerfully inhibit its ability to bind to Abeta oligomers.

We propose here to: (1) characterize at the atomic level the site on PrPC to which our lead compounds bind; (2) optimize the molecular scaffold of these compounds using structure-activity analyses and structure-based design methods; and (3) test whether these compounds and their derivatives suppress the synaptotoxic effects of Abeta oligomers in cellular and animal models.
The Abeta peptide is a central player in Alzheimer's Disease (AD). Abeta is processed from the full length Amyloid Precursor Protein and populates large plaques throughout the brain. However, smaller oligomeric species are widely believed to cause cell death. Unfortunately, efforts to reduce Abeta processing or promoting clearance have largely failed. We have thus created a much simpler model of Abeta toxicity for unbiased phenotypic screens free of prejudice about mechanism. To this end, we use the budding yeast, Saccharomyces cerevisiae, to capture agents that reduced Abeta toxicity. Though lacking the complexities of a nervous system, yeast offer nearly all of the conserved cellular pathways involved in most aspects of basic eukaryotic cell biology, including the sophisticated protein homeostasis mechanisms that cope with the cellular stresses imposed by toxic neurodegenerative disease proteins. In the yeast model of Abeta toxicity, the peptide is targeted to the endoplasmic reticulum and samples the secretory pathway. A genetic screen against Abeta toxicity identified the yeast homolog of PICALM, a risk factor for AD in humans. We validated genetic modifiers in both a C. elegans model and an Abeta oligomer assay in rat neuronal cultures. For this proposal, we have one completed and one ongoing phenotypic drug screen for compounds that combat Abeta toxicity. Importantly, we identified the AD-relevant compound clioquinol (CQ), which rescues Aβ toxicity and cognition in a mouse model of AD. A close derivative of this compound has shown promise in early clinical trials. Here, we propose to enter the compounds that reduce Abeta toxicity into a pipeline of secondary screens, neuronal assays, and medicinal chemistry. We will partner with chemist Stephen Buchwald (MIT) to perform extensive structure activity relationships. We propose to structurally and mechanistically characterize several compounds protective against Aβ toxicity, taking advantage of yeast genetics and cell biology.
Deposition of the microtubule associated protein tau is associated with a number of neurodegenerative disorders. The most common tauopathy is Alzheimer’s disease, which contains both tau deposits and amyloid deposits in affected brain regions. To date, there are no effective treatments targeting tau deposition.

Histone deacetylase 6 (HDAC6) is an enzyme that removes acetyl groups from lysine containing proteins. Two substrates of HDAC6 are acetylated tubulin and acetylated heat shock protein 90 (HSP90). Histone proteins do not appear to be substrates for this family member. HSP90 is a chaperone that is a decision point in the life cycle of misfolded proteins, leading to either refolding or to degradation. Tau is one of the clients served by HSP90. Recent work by the Petrucelli group indicates that acetylation of HSP90 shifts the balance towards degradation. Thus inhibition of HDAC6 leads to an increase in the acetylated form of HSP90 and increased degradation of its client proteins, including tau.

We have tested a selective HDAC6 inhibitor tubastatin A in a mouse model of tau deposition (Tg4510). We found that daily injections of tubastatin rescue memory deficits in these mice, and reduce total tau, but not phosphorylated forms, in the mouse brain. These data suggest that selective HDAC6 inhibitors may be useful therapeutic approaches for the treatment of Alzheimer’s and other tauopathies.

To further test this hypothesis, we propose 2 aims:
Aim 1. Optimizing tubastatin dose and administration. We will treat mice with multiple doses an measure brain an blood concentrations and accumulation of acetylated HDAC6 targets using oral administration.

Aim 2. Time course of tubastatin effects on the phenotype of Tg45410 mice. This aim will test whether initiating treatment early will demonstrate greater protection and if the rescue of the phenotype can be sustained over time.
Edward N. and Della L. Thome Memorial Foundation, Bank of America, N.A. Trustee, Awards Program in Alzheimer’s Disease Drug Discovery Research
2012 Award Recipient

Luigi Puglielli, M.D., Ph.D.
Associate Professor
University of Wisconsin-Madison

"ATase1/ATase2 inhibitors for the prevention of Alzheimer’s disease"

Our group has identified a novel form of post-translational regulation that affects both levels and activity of BACE1. Specifically, we discovered that nascent BACE1 is transiently acetylated in the lumen of the ER by two acetyltransferases, which we named ATase1 and ATase2. The acetylated intermediates of nascent BACE1 are able to complete maturation whereas non-acetylated intermediates are rapidly degraded. Consistently, up-regulation of ATase1 and ATase2 increases BACE1 levels and Abeta generation while down-regulation has the opposite effects. Both ATase1 and ATase2 are preferentially expressed in neurons and are up-regulated in the brain of late-onset AD patients. Following up on our initial discovery, we have now identified novel biochemical inhibitors of ATase1 and ATase2 that significantly reduce the levels of BACE1 and the generation of Abeta in cellular systems. The mechanism of action of the compounds involves competitive and non-competitive inhibition as well as generation of unstable intermediates of the ATases that undergo degradation. Here, we report the completion of the physical/chemical (pre-formulation) characterization and formulation development phase and successful transition to animal models of the disease. The initial results in AD animal models show successful changes in BACE1 and APP metabolism as well as prevention of the early deficits that characterize the AD-like pathology of the animals. The general hypothesis of this research is that biochemical inhibitors of ATase1 and ATase2 can serve to prevent or delay AD dementia. Specific Aim 1 will assess whether recently identified compounds that inhibit ATase1 and ATase2 activity can delay or block AD-like neuropathology in animal models of the disease. Specific Aim 2 will characterize the biochemical properties as well as mechanism of action of two new active compounds that inhibit ATase1 and ATase2 in vitro and reduce BACE1 levels in cell-based settings.
Histone Acetyltransferase (HAT) Activators as Chromatin Remodelers for the Treatment of Memory Loss in Alzheimer’s Disease

Amyloid-beta, a peptide that is present in high amounts in Alzheimer’s Disease (AD), has been found to inhibit memory and its electrophysiological model, long-term potentiation (LTP). Amyloid-beta was also found to reduce histone acetylation, a chromatin modification that is important for the formation of memory. The main strategy that is currently used to up-regulate histone acetylation involves HDAC inhibitors. However, the pleiotropic effect of nonspecific HDAC inhibition may hamper their therapeutic potential. Activators of histone acetyltransferase (HAT) might constitute an alternative avenue to enhance histone acetylation. To this end, in preliminary experiments, hippocampal levels of two HATs, CBP and PCAF, were found to be reduced following amyloid-beta elevation. Most importantly, a newly-designed HAT activator, YF2, which is soluble, membrane permeable and blood-brain barrier permeant, was found to i) enhance enzymatic activity of PCAF and CBP in an in vitro assay; ii) increase specific histone acetylation of of H3, H4 and H2B in hippocampal lysates, iii) rescue deficits in LTP as well as fear and reference memory induced by amyloid-beta. A course of investigation involving the design of selective HAT activators that target specifically CBP and PCAF, downstream of amyloid-beta is proposed in this application. The aims of our proposal are: 1) to design and synthesize novel HAT activators which are optimized for AD; 2) to identify new HAT activators with high affinity and good selectivity for CBP and/or PCAF; 3) to determine if new HAT activators have good pharmacokinetic profile and are safe; 4) to select HAT activators that rescue synaptic dysfunction in a mouse model of amyloid-beta elevation; 5) further screen HAT activators to determine if they are beneficial against cognitive abnormalities in a mouse model of amyloid-beta elevation. On the completion of these studies we will identify a new drug for the treatment of cognitive loss in AD.
Edward N. and Della L. Thome Memorial Foundation, Bank of America, N.A. Trustee, Awards Program in Alzheimer’s Disease Drug Discovery Research 2010 Award Recipient

Luciano D’Adamio, M.D.
Professor, Department of Microbiology & Immunology
Albert Einstein College of Medicine of Yeshiva University, NY, United States

Translation of BRI2 Derived Peptides into Therapeutic Candidates

Alzheimer’s Disease is the most common cause of dementia in the world and the 6th leading cause of death in our nation. It increases exponentially with age, afflicting an estimated 1% of individuals aged 60-64 years and nearly 50% of those 85 years or older. Longer life spans coupled with the changing demography of the aging baby boomers renders AD a pressing public-health issue. However current treatments only modestly retard the progression of the illness because they treat the symptoms rather than the cause of the disease. Genetic data indicate that APP processing and APP metabolites play a pivotal role in AD. A possible approach to develop therapeutic strategies for AD involves the characterization of the biological pathways/molecules that regulate APP processing. Understanding how APP cleavage is physiologically regulated might suggest therapeutic interventions that are otherwise unimaginable. Recently, we found that BRI2 is a ligand of APP that regulates APP cleavage. BRI2 hides the cleavage site of APP from BACE and the γ-secretase and reduces APP cleavage by secretases. In doing so, BRI2 selectively reduces APP processing while leaving the secretases undisturbed to act on other substrates. To take advantage of this function we have produced BRI2-derived peptides that mimic its role. These BRI2-peptides inhibit APP cleavage by BACE and also interfere with the toxicity of Aβ42 oligomers that are derived by APP processing. Thus, we will refer to these peptides as IAPT (Inhibitor of APP Processing and Toxicity). This grant aims to perform lead optimization on the parent peptides in terms of absorption, distribution, metabolism, excretion, toxicity (ADMET) and general pharmacokinetics. We will also seeks to identify small-molecules that retain BRI2-like biological activity but have ADMET properties suitable for oral-administration as therapeutics to treat AD in patients. Advanced leads will be qualified by evaluation in animal models of dementia.
Todd Golde, M.D., Ph.D.
Professor and Director, Center for Translational Research in Neurodegenerative Disease,
Department of Neuroscience
University of Florida, FL, United States

Amyloid Vaccines and Human Anti-Amyloid Antibodies

There is compelling evidence that aggregation and accumulation of the amyloid beta protein (Abeta) in the brain plays a pivotal role in Alzheimer’s Disease (AD), "triggering" a complex neurodegenerative cascade. Thus, numerous therapeutic modalities targeting Abeta and Abeta aggregates are in the developmental pipeline. Among the most promising of the anti-Abeta based therapeutic approaches for AD are Abeta vaccines and humanized anti-Abeta monoclonal antibodies. For reasons discussed more extensively below, it is highly likely that the clinical efficacy of disease modifying effects of these and other anti-Abeta therapies will be highly dependent on the extent of underlying pathology present at the time of initiation of treatment. Indeed, a therapy which fails to show efficacy in the symptomatic patient might show remarkable efficacy with respect to preventing the development of AD or slowing the conversion from preclinical AD to symptomatic AD.

The implementation of prophylactic or very early intervention trials with anti-Abeta therapeutics will likely require the development of therapies that are as safe as possible. Here, we propose to develop novel active and passive AD immunotherapies that have potential to be safer, more efficacious, and possibly more cost-effective, than current approaches. The overall rationale is that Abeta aggregates, not monomeric Abeta, are the ideal targets of immunotherapy. Specifically, we propose two complementary and synergistic aims:

1. Optimization and pre-clinical validation in AD mouse models of heterologous amyloid (HAPs) vaccines that result in robust humoral immune responses to Abeta amyloid (as well as other potentially pathogenic amyloids), but not monomeric Abeta or other APP derivatives.

2. Identification and characterization of human (as opposed to humanized) anti-amyloid antibodies that target Abeta aggregates with minimal targeting of Abeta or APP derivatives and validation of their efficacy.
Edward N. and Della L. Thome Memorial Foundation, Bank of America, N.A. Trustee,
Awards Program in Alzheimer’s Disease Drug Discovery Research
2010 Award Recipient

Gary Landreth, Ph.D.
Professor, Department of Neurosciences
Case Western Reserve University, OH, United States

ApoE-directed Therapeutics for the Treatment of Alzheimer’s Disease

We propose to develop new drugs that promote Abeta clearance from the brain by targeting the transcriptional machinery regulating the expression of ApoE and its incorporation into HDL particles. Lipidated forms of ApoE act normally to promote the proteolytic degradation of Abeta. Importantly, elevation of ApoE levels in the brain is associated with reduction in Abeta levels and plaque burden and improved cognition in animal models of AD. We propose to investigate drugs that target the ligand-activated transcription factors, retinoid X receptors (RXRs), which regulate the synthesis of ApoE and the formation of HDL.

We show that the rexinoid, bexarotene, stimulates the expression of ApoE and highly lipidated HDLs. Elevation of ApoE levels promote the degradation of Abeta in the brain. We provide preliminary data demonstrating that oral treatment of APP/PS1 mice for 7 days with the FDA approved RXR agonist, bexarotene (TargretinTM), increases the levels of ApoE in the brain leading to a reduction in plaque load and Aâ levels by 65% and improved cognition. In vivo microdialysis demonstrated that within 24 hrs of drug administration there was a 30% decrease in interstitial Abeta levels owing to a 70% reduction in Abeta half life. Bexarotene freely passes the blood-brain barrier.

Aim 1 will establish if bexarotene is a viable candidate for clinical development. We propose to determine optimal drug dosage and scheduling of its administration that result in reduced amyloid pathology and improved behavior.

Aim 2 is directed at the development of new chemical entities that act as selective modulators of RXRs. The principal side effect of bexarotene is triglyceridosis, owing to stimulation of SREBP1c expression. Selective RXR modulators act to differentially promote receptor activity at individual target gene promoters. We will modify the bexarotene scaffold to minimize SREBP1c activity and maximize activity at the ApoE and ABCA1 promoters.
Glutamate-mediated excitotoxicity is involved in the pathogenesis of Alzheimer’s Disease (AD). Excitotoxicity is defined as excessive exposure to the neurotransmitter glutamate or overstimulation of its membrane receptors such as NMDA receptors. This overstimulation can lead to neuronal injury or death. A therapeutic target has been to reduce excitotoxicity through modulation of the glutamate neurotransmitter system. Memantine, an uncompetitive NMDA-receptor antagonist that inhibits pathological functions of NMDA receptors, has been approved for treating the advanced stages of AD. Memantine is a relatively safe drug with few side effects but only small clinical relevant effects on cognition, global functioning, and activities of daily living. The major factor causing excitotoxicity in AD is the impairment of glutamate reuptake function. It is primarily due to the loss of glial glutamate transporter EAAT2, the major glutamate transporter in the central nervous system. One potential therapeutic approach to prevent excitotoxicity is to activate EAAT2 protein expression and boost glutamate uptake function. In collaboration with the Laboratory of Drug Discovery in Neurodegeneration (LDDN) at the Harvard Medical School, we executed high-throughput screen to identify compounds that can activate EAAT2 expression. This screen resulted in the discovery of two promising classes of EAAT2 translational activators. The goals of this study are to optimize and characterize these two lead series and to assess whether these EAAT2 expression activators can ameliorate Alzheimer’s-like pathology and behavior in APPSw/Ind mice.
Edward N. and Della L. Thome Memorial Foundation, Bank of America, N.A. Trustee, Awards Program in Alzheimer’s Disease Drug Discovery Research 2010 Award Recipient

Joseph Ready, Ph.D.
Associate Professor, Department of Biochemistry
U.T. Southwestern Medical Center, TX, United States

Optimization of Neuroprotective, Pro-Neurogenic Small Molecules for Treatment of Alzheimer’s Disease

Alzheimer’s Disease (AD) is characterized by neurodegeneration, so drugs that improve neural structure and function may represent valuable treatments. Specifically, we have targeted neurogenesis in the hippocampus. The hippocampus is involved in learning and memory, and is one of the first regions to be damaged in AD. This region uniquely generates new neurons throughout adulthood, and is critical for learning and memory. AD patients display altered patterns of neurogenesis, and might benefit from agents that normalize this activity. Enhancement of neurogenesis in mouse models of AD can ameliorate cognitive deficits. We hypothesize that the cognitive deficits in AD can be treated with small molecules that promote the formation and survival of functional neurons within the hippocampus. Accordingly, we aim to develop neuroprotective, pro-neurogenic small molecules that will prevent or reverse cognitive decline associated with Alzheimer’s Disease. Compounds will be optimized for efficacy, bioavailability, metabolic stability and absence of toxicity. We have identified a small molecule named P7C3 that promotes hippocampal neurogenesis in mice and rats. This drug-like substance repairs the structure and function of malformed hippocampuses, and prevents age-associated cognitive decline in rats. It protects newborn neurons from cell death and allows them to differentiate into fully integrated mature neurons. It distributes into the CNS, is non-toxic to embryonic, weaning or adult mice, and is active at 5 mg/kg oral dose. We plan to mount a medicinal chemistry campaign to optimize the potency and CNS-penetration of P7C3. Simultaneously, we will optimize compounds for metabolic stability and the absence of toxicity or off-target interactions. Compounds will be tested in mice and rats for bioavailability, half-life, ability to promote neurogenesis, and capacity to improve cognition and memory in mice models of AD. Our objective is to identify small molecules suitable for advancement to IND-enabling studies by the end of this project.
Screening for New Drugs to Treat Alzheimer’s Disease

Alzheimer’s Disease (AD) is a neurodegenerative disorder that leads to dementia. There is increasing evidence of a vascular contribution in AD. Many AD patients suffer from altered cerebral blood flow, damaged cerebral vasculature, and abnormal hemostasis. Circulatory deficiencies could therefore play an important role in this disease. However, a mechanism underlying a vascular contribution in AD is unclear. We have found that the deposition of fibrin(ogen), the primary protein component of blood clots, plays a role in exacerbating pathology and cerebrovascular dysfunction in AD mouse models. We also found that that the beta-amyloid peptide binds specifically to fibrinogen and that fibrin clots formed in the presence of beta-amyloid have an abnormal structure, making them resistant to degradation by fibrinolytic enzymes. These results indicate that in the presence of beta-amyloid, any fibrin clots formed are more persistent and exacerbate blood brain barrier damage, neuroinflammation, and neuronal death. Therefore, molecules that block this interaction could restore the normal structure of fibrin clots and could be used as therapeutic agents.

We have designed a high throughput screen to identify small molecules that inhibit the interaction between beta-amyloid and fibrinogen. We have screened compounds using two complementary assays: fluorescence polarization and AlphaLISA. We have identified three candidate compounds, and their half-maximal inhibition (IC50) ranges between 1 μM and 20 μM. These results suggest that our screening strategy is effective for identification of small molecules that inhibit the interaction between beta-amyloid and fibrinogen. We hope to expand our screening with a wide range compound library to find the most potent compounds and improve upon our candidate compounds using structure-activity relationships and pharmacokinetic studies. In addition, we will validate our hit compounds using functional studies such as intravital microscopy and mouse behavior. We hope our candidate inhibitors will become effective drug therapies for treating AD patients.
Edward N. and Della L. Thome Memorial Foundation, Bank of America, N.A. Trustee, Awards Program in Alzheimer’s Disease Drug Discovery Research 2010 Award Recipient

Linda Van Eldik, Ph.D.
Professor, Department of Anatomy and Neurobiology and Director, Sanders-Brown Center on Aging
University of Kentucky Research Foundation, KY, United States

Refinement of p38alpha MAPK inhibitors for Alzheimer’s Disease

This project’s goal is to de-risk a novel, CNS-penetrant, efficacious, small molecule in order to identify a new therapeutic candidate for Alzheimer’s Disease (AD). The initial lead compound and its more refined analog were developed through structure-assisted, selective ligand targeting of p38alphaMAPK, a key protein kinase that drives stressor-induced proinflammatory cytokine overproduction and is involved in neuronal homeostasis. The p38alphaMAPK isoform is a validated therapeutic target for peripheral tissue disorders, but extension to CNS disorders was limited by the need for adequate CNS penetrance with retention of selective inhibitory activity. To address this problem, we used our discovery engine that integrates informatics and computational biology with pharmacology experimental filters, providing a recursive, drug discovery focused effort. The initial small molecule, cmpd069A, is a selective p38alphaMAPK inhibitor that is brain penetrant and shows efficacy in an AD-relevant animal model that exhibits the targeted mechanism of pathology progression. The recursive nature of the discovery engine yielded several second-generation inhibitors, with cmpd181 exhibiting promising pharmacology profiles with retention of p38alphaMAPK inhibitor activity.

Growing evidence has implicated p38alphaMAPK in CNS disorders, including AD. Activation of p38alphaMAPK is an early event in AD, is linked to cytokine overproduction and synaptic dysfunction, and correlates with pathology progression. This project is an early step in testing the hypothesis that orally bioavailable, brain-penetrant, small molecule p38alphaMAPK inhibitors can be developed into effective future AD therapeutics.

Our specific aims are:

Aim 1. Subject cmpd181 to pharmacological screens that de-risk the potential for failure in later-stage preclinical, IND-enabling investigations. As needed, perform medicinal chemistry refinement in an effort to identify the best candidate(s) for follow-on development with industrial partners.

Aim 2. Determine dose-dependent efficacy in AD-relevant animal models as a selection criterion among refined candidate compounds.

The deliverable will be identification of at least one candidate for future clinical development.